Novavax to supply Covax with 1.1B COVID-19 vaccine doses

By The Science Advisory Board staff writers

February 22, 2021 -- Novavax announced a memorandum of understanding with Gavi, the Vaccine Alliance, to provide 1.1 billion cumulative doses of its COVID-19 vaccine candidate, NVX-CoV2373, to the Covax facility. The company has also fully enrolled participants in its pivotal phase III clinical trial of NVX-CoV2373.

Covax was established by public health agencies, including the World Health Organization, to provide governments with early access to a large portfolio of COVID-19 vaccines.

The vaccine will be manufactured and distributed globally by Novavax and the Serum Institute of India (SII). Novavax licensed its vaccine to SII with no upfront, milestone, or technology transfer payments. Novavax and SII are jointly committed to deliver 1.1 billion doses to the Covax facility.

Gavi will work with Novavax to finalize an advance purchase agreement for vaccine supply and global distribution allocation via the Covax facility and its partners.

The company also announced that it has completed enrollment of its Prevent-19 phase III study in the U.S. and Mexico to evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373. The study has enrolled 30,000 individuals from diverse populations. Two-thirds of the participants are assigned to randomly receive two intramuscular injections of the vaccine, administered 21 days apart, while one-third of the trial participants receive a placebo. Prevent-19 is being conducted with support from the U.S. government partnership.

Copyright © 2021

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.